which is designed to stimulate an immune response against toxic forms of amyloid in order to clear them from the body. If the drug reaches the market, AC Immune is also in line for mid-to-high ...

The FDA has approved the sBLA for once every 4 weeks lecanemab-irmb (Leqembi®) intravenous maintenance dosing.

It seems Eisai and Biogen have another hurdle to jump over in their bid to get EU approval for their Alzheimer's disease therapy Leqembi ... or no copy of ApoE4, a form of the gene for the ...

The U.S. Food and Drug Administration (FDA) has approved monthly maintenance dosing for Leqembi (lecanemab), a treatment for early Alzheimer’s disease.

Between 42–44% of respondents also use tall man lettering at their facility for similar drug names that appear on computerized prescriber order entry (CPOE) screens, smart pump libraries ...

ISMP has long been an advocate for the use of standard order sets to minimize incorrect or incomplete prescribing, standardize patient care, and ensure clarity when communicating medical orders.

DMTs come in three different forms: injections, oral therapies, and IV infusions. Many DMTs have been FDA-approved to treat relapsing forms of MS in adults, which includes relapsing-remitting MS and ...